Ad26.COV2.S
Phase 3Biologic
Johnson & JohnsonAd26.COV2.S is one of 83 biologic programs targeting Autoimmune Disease. It is currently in Phase 3.
3
Indications
15
Total Trials
1
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Ad26.COV2.S
Johnson & JohnsonPhase 3
Bnt162b2
BioNTechPreclinical
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Benadryl
PParkedale
Preclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
COVID-197 trials
Vaccination2 trials
SARS-CoV-21 trial
Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT04889209·867 enrolled
Adolescent1 trial
Autoimmune Disease1 trial
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05000216·258 enrolled
3 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ad26.COV2.S. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company